Viridian Therapeutics/VRDN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Viridian Therapeutics

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Ticker

VRDN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Stephen Mahoney

Employees

96

Headquarters

Waltham, United States

VRDN Metrics

BasicAdvanced
$763M
Market cap
-
P/E ratio
-$4.50
EPS
1.06
Beta
-
Dividend rate
$763M
1.06337
$28.35
$10.93
908K
23.991
3.49
3.49
-42.89%
-72.90%
-45.38%
2,648.189
1.992
1.309
-82.59%
3.40%
-33.13%

What the Analysts think about VRDN

Analyst Ratings

Majority rating from 15 analysts.
Buy

VRDN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$49M
-27.40%
Profit margin
0.00%
NaN%

VRDN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 28.43%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.27
-$1.09
-$1.35
-$0.79
-
Expected
-$1.29
-$1.27
-$1.00
-$1.10
-$0.90
Surprise
-1.89%
-13.91%
34.59%
-28.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Viridian Therapeutics stock?

Viridian Therapeutics (VRDN) has a market cap of $763M as of June 15, 2024.

What is the P/E ratio for Viridian Therapeutics stock?

The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of June 15, 2024.

Does Viridian Therapeutics stock pay dividends?

No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Viridian Therapeutics dividend payment date?

Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.

What is the beta indicator for Viridian Therapeutics?

Viridian Therapeutics (VRDN) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Viridian Therapeutics stock price target?

The target price for Viridian Therapeutics (VRDN) stock is $36.5, which is NaN% below the current price of $. This is an average based on projections from 14 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Viridian Therapeutics stock

Buy or sell Viridian Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing